Therapeutic Inhibitors against Mutated BRAF and MEK for the Treatment of Metastatic Melanoma

• Published in: Chonnam medical journal Vol. 53; no. 3; pp. 173 - 177
• Main Authors: Ryu, Sunhyo, Youn, Chakyung, Moon, Ae Ran, Howland, Amanda, Armstrong, Cheryl A, Song, Peter I
• Format: Journal Article
• Language: English
• Published: Korea (South) Chonnam National University Medical School 01-09-2017; 의과학연구소
• Subjects: Review; 의학일반; Dabrafenib; Vemurafenib; Mitogen-activated protein kinase kinases; Sorafenib; Melanoma
• ISSN: 2233-7385; 2233-7393
• DOI: 10.4068/cmj.2017.53.3.173

Melanoma is one of the most aggressive cancers in the world and is responsible for the majority of skin cancer deaths. Recent advances in the field of immunotherapy using active, adoptive, and antigen-specific therapeutic approaches, have generated the expectation that these technologies have the potential to improve the treatment of advanced malignancies, including melanoma. Treatment options for metastatic melanoma patients have been dramatically improved by the FDA approval of new therapeutic agents including vemurafenib, dabrafenib, and sorafenib. These kinase inhibitors have the potential to work in tandem with MEK, PI3K/AKT, and mTOR to inhibit the activity of melanoma inducing BRAF mutations. This review summarizes the effects of the new therapeutic agents against melanoma and the underlying biology of these BRAF inhibitors.